LOGIN  |  REGISTER
Chimerix
Terns Pharmaceuticals

Neogen Establishes Relationship with Biomatter

August 11, 2025 | Last Trade: US$5.88 0.05 -0.84

LANSING, Mich. / Aug 11, 2025 / Business Wire / Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that it has entered into an arrangement with Biomatter, a leading enzyme design company, to leverage Biomatter’s proprietary Intelligent Architecture™ platform and Neogen’s expertise in the field of analytical development and technology to create new enzyme-based products.

Biomatter’s Intelligent Architecture™ platform, based on AI and Physical modelling, enables the design of enzymes with unique capabilities, dramatically expanding how they can be used in food safety related applications.

“This relationship marks a significant step forward in advancing food security,” said Dr. Jason Lilly, Neogen’s Chief Scientific Officer. “By combining our leadership and innovation in food testing and risk mitigation with Biomatter’s cutting-edge enzyme engineering capabilities, we’re unlocking new possibilities that can enhance detection, improve efficiency, and ultimately protect and enhance the quality and safety of the global food supply.”

“It is a privilege to partner with Neogen to create new enzymes that will push the boundaries of food and animal safety solutions,” said Laurynas Karpus, Biomatter’s Chief Executive Officer. “Together, our teams aim to set new standards in the industry, making every step of the process more efficient, cost-effective, and ultimately more beneficial for the end user.”

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

About Biomatter

Biomatter is a next-generation enzyme design company breaking the limits of traditional protein engineering. Leveraging its generative AI-powered Intelligent Architecture™ platform, the company designs novel, high-performance enzymes from the ground up. Through collaborations with industry leaders in medicine, diagnostics, agriculture, and biomanufacturing, Biomatter delivers unique enzymatic solutions that enable differentiated products and promote a healthier, more sustainable world. Discover more at www.biomatter.ai.

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page